Can DFN-15 Terminate Migraine With Allodynia?

Hartford Hospital (Other)
Overall Status
Completed ID
Rami Burstein, PhD, Beth Israel Deaconess Medical Center (Other), Dr. Reddy's Laboratories Limited (Industry)

Study Details

Study Description

Brief Summary

The majority of migraineurs seeking secondary or tertiary medical care develop cutaneous allodynia during the course of migraine, a sensory abnormality mediated by sensitization of central trigeminovascular neurons in the spinal trigeminal nucleus. Triptan therapy can render allodynic migraineurs pain-free within a narrow window of time (20-120 min) that opens with the onset of pain and closes with the establishment of central sensitization. This calls for the development of drugs that can tackle ongoing central sensitization and render allodynic migraineurs pain-free after the window for triptan therapy has expired. There are two main objectives the investigators seek to achieve from this study: to determine whether oral administration of DFN-15 (solution of a COX2 inhibitor, Celecoxib) terminates migraine attacks when given to allodynic participants 3 hours after attack onset; and to determine whether mechanical and heat allodynia that develop during acute migraine attacks could be reversed by late (> 3hrs after attack onset) treatment with DFN-15. Participants will be recruited from the Headache Center and randomized in a double-blinded fashion to receive either the active drug (DFN-15) or placebo in a ratio of 4:1.The participants will be instructed to return to the clinic during a migraine. At the 'during-migraine' visit, which will begin 3 hours after onset of headache, the investigators will document headache intensity, associated symptoms, and mechanical and heat pain threshold (first) before treatment (at 180 min after onset of headache) and (second) at a 120 min after treatment (5 hours after headache onset). Based on our prior experience studying migraine patients, the investigators plan to screen 100 patients to achieve 50 participants completing the 2 study visits as planned. The active drug group will consist of 80/100 patients and 20/100 patients will receive the placebo. The study will be terminated as soon as the first 40 participants who received the DFN-15 and first 10 patients who received placebo completed visit 2.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Actual Enrollment :
51 participants
Intervention Model:
Parallel Assignment
Double (Participant, Investigator)
Primary Purpose:
Official Title:
Effects of DFN-15 on Migraine With Allodynia
Actual Study Start Date :
May 9, 2018
Actual Primary Completion Date :
Apr 12, 2019
Actual Study Completion Date :
Apr 12, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Treatment Group


Drug: DFN-15
Oral Solution of 4.8 mL containing 120 mg of DFN-15
Other Names:
  • Celecoxib
  • Placebo Comparator: Placebo Group

    Other: Placebo
    Oral Solution of 4.8 mL containing 0 mg of DFN-15

    Outcome Measures

    Primary Outcome Measures

    1. Headache Pain Intensity [Up to 6 months]

      The proportion of patients demonstrating a decrease in their headache pain intensity is greater than 50% (post-treatment compared to pre-treatment). Pain intensity will be measured with a visual analog scale from 0 (no pain) to 10 (worst pain imaginable).

    Secondary Outcome Measures

    1. Allodynia [Up to 6 months]

      The proportion of patients demonstrating allodynia before and after treatment; allodynia to thermal stimuli is defined as pain threshold < 41 degrees Celsius, and to mechanical stimuli as pressure pain threshold of < 30 g.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years to 64 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • History of migraine with or without aura for at least 3 years, based on the International Classification of Headache disorders

    • Two or more migraine attacks per month on average during the year prior to enrollment

    • Ability to give written consent to enrollment

    Exclusion Criteria:
    • Fifteen or more headache days per month, on average

    • Aspirin or NSAID induced asthma or allergy

    • Sulfa allergy

    • Any woman who is pregnant or lactacting

    • History of any of the following: Coronary artery bypass surgery, heart attack, angina, stroke, serious gastrointestinal bleeding, peptic ulcer disease, and/or chronic kidney disease

    • Medical Conditions requiring the use of diuretics or daily anticoagulants

    • Severe uncontrolled medical problems or medications that may influence measurements

    Contacts and Locations


    Site City State Country Postal Code
    1 Hartford HealthCare Headache Center West Hartford Connecticut United States 06107

    Sponsors and Collaborators

    • Hartford Hospital
    • Rami Burstein, PhD, Beth Israel Deaconess Medical Center
    • Dr. Reddy's Laboratories Limited


    None specified.

    Study Documents (Full-Text)

    More Information


    None provided.
    Responsible Party:
    Brian Grosberg, Brian M Grosberg, MD, Hartford Hospital Identifier:
    Other Study ID Numbers:
    • HHC-2017-0224
    First Posted:
    Mar 21, 2018
    Last Update Posted:
    Apr 16, 2019
    Last Verified:
    Apr 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Product Manufactured in and Exported from the U.S.:
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 16, 2019